Xeris Biopharma Holdings, Inc. Common Stock
XERSXeris Biopharma Holdings, Inc. develops and commercializes injectable and oral formulation pharmaceuticals. Focused on innovative delivery platforms, the company aims to improve treatment options for various chronic conditions, including diabetes, hypoglycemia, and other endocrine disorders. Its products often feature liquid-stable formulations designed for ease of use and rapid administration.
Company News
Xeris Biopharma reported strong Q2 2025 financial results, with revenue jumping 48.8% year-over-year to $71.5 million, driven by significant growth in Recorlev sales. The company raised its full-year revenue guidance and showed a positive turn in adjusted EBITDA.
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Xeris Biopharma's financial success in compounding healthcare investing may be uncertain due to competition and FDA approval risks. Read more on XERS stock here.
Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
